Fusion Pharmaceuticals Inc.
RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY
Last updated:
Abstract:
Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.
Status:
Application
Type:
Utility
Filling date:
2 Jun 2021
Issue date:
23 Sep 2021